Moderna(MRNA)
搜索文档
Moderna(MRNA) - 2024 Q3 - Quarterly Results
2024-11-07 19:33
2024年营收相关 - 2024年第三季度营收19亿美元GAAP净收入1300万美元GAAP每股收益0.03美元[1] - 2024年年初至今产品销售额22亿美元重申2024年产品销售额预期为30 - 35亿美元[1] - 2024年前三季度净产品销售额为21.71亿美元2023年同期为38.78亿美元[29] - 2024年前三季度其他收入为0.99亿美元2023年同期为1.59亿美元[29] - 2024年前三季度总营收为22.70亿美元2023年同期为40.37亿美元[29] 特定产品销售额 - 2024年第三季度Spikevax®销售额18亿美元其中美国销售额12亿美元国际销售额6亿美元[2] - 2024年第三季度mRESVIA®销售额1000万美元[4] - 2024年第三季度净产品销售额18亿美元同比增长4%[5] - 重申2024年呼吸类产品净销售额预期为30 - 35亿美元[12] 成本相关 - 2024年第三季度销售成本5.14亿美元较2023年同期下降77%占净产品销售额的28%[6] - 2024年第三季度研发费用11亿美元较2023年第三季度下降2%[7] - 2024年第三季度销售一般和管理费用2.81亿美元较2023年第三季度下降36%[8] - 2024年全年研发费用预计为46 - 47亿美元[12] 盈亏相关 - 2024年前三季度运营亏损为26.99亿美元2023年同期为42.45亿美元[29] - 2024年前三季度净亏损为24.41亿美元2023年同期为49.31亿美元[29] 现金相关 - 截至2024年9月30日现金及现金等价物为16.44亿美元截至2023年12月31日为29.07亿美元[30] - 2024年前三季度经营活动现金净流出为38.29亿美元2023年同期为37.40亿美元[31] - 2024年前三季度投资活动现金净流入为24.88亿美元2023年同期为47.44亿美元[31] - 2024年前三季度融资活动现金净流入为0.59亿美元2023年同期为净流出12.68亿美元[31] 前瞻性陈述 - 公司对2024年财务框架和预期业绩包括预期产品销售等作出前瞻性陈述[33]
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga· 2024-11-07 14:37
Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion for the quarter, compared to $1.83 billion a year earlier, according to data from Benzinga Pro.On Oct. 28, On Monday, Merck & Co Inc MRK and Moderna announced the initiation of INTerpath-009, a pi ...
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?
ZACKS· 2024-11-05 22:31
Moderna (MRNA) is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.Estimates for Moderna’s 2024 loss per share have increased from $9.52 to $9.88 in the past 60 days. During the same period, estimates for 2025 loss per share have risen from $7.37 to $8.59. Image Source: Zacks Investment Re ...
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
ZACKS· 2024-10-30 06:56
Moderna (MRNA) closed the latest trading day at $55.22, indicating a +0.77% change from the previous session's end. This change outpaced the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a drop of 0.37%, and the technology-dominated Nasdaq saw an increase of 0.78%. Prior to today's trading, shares of the biotechnology company had lost 18% over the past month. This has lagged the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67% in that time. Investors will be eagerly watching ...
We Think Moderna Still Has A Future
Seeking Alpha· 2024-10-23 04:56
文章核心观点 - 公司Moderna的新冠疫苗需求下降,导致股价持续疲软,但公司仍有20亿美元的市值,凭借其丰富的资产组合继续获利[1] - 投资组合专家通过深入研究公司财报、分析师评论、市场报告等,采用事实为基础的研究策略,为退休投资者建立投资组合[1] 公司概况 - Moderna是一家拥有20亿美元市值的公司[1] - 公司凭借其丰富的资产组合继续获利[1] 投资策略 - 投资组合专家采用事实为基础的研究策略,包括深入研究公司财报、分析师评论、市场报告等[1] - 专家为退休投资者建立投资组合[1]
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?
ZACKS· 2024-10-16 22:51
Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have lost significantly in the past couple of years due to declining sales amid low demand for the vaccine. In the past month, MRNA stock fell more than 20% after management provided an update on its business outlook for the next four years. It also announced plans to slash its research and development (R&D) budget during this period. In the past month, the stock has underperformed the industry's 2.3% ...
mRNA Therapeutics Industry Research 2024-2028 & Long-term Forecast to 2033: Emerging Self-Amplifying mRNA Platforms, Scalability and Flexibility Expected to Revolutionize Vaccine Development
GlobeNewswire News Room· 2024-10-15 16:03
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA therapeutics market size has grown steadily in recent years. It will grow from $33.5 billion in 2023 to $34.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $40.69 billion in 2028 at a compound annual growth rate (CAGR) of 4%. During ...
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way
GlobeNewswire News Room· 2024-10-14 23:48
文章核心观点 - mRNA癌症疫苗和治疗市场规模近年来增长迅速,预计未来几年将继续保持快速增长 [1][2][3] - 市场增长的主要驱动因素包括生活方式变化导致的医疗需求增加、医疗研发投资支持增加、监管环境有利于创新、成熟的医疗基础设施以及新疗法管线的不断发展 [2][3] - 未来增长将得益于临床试验的有希望结果、mRNA技术在癌症治疗中的认知和接受度提高、巨大的未满足医疗需求、可能带来的更好的患者预后以及现成治疗方案的前景 [3] - 主要趋势包括拓展新的治疗领域、采用个性化医疗方法、mRNA递送系统的进步、针对多个抗原的多价mRNA疫苗开发以及人工智能和机器学习在优化mRNA设计中的应用 [3] 行业概况 - 癌症发病率上升将推动mRNA癌症疫苗和治疗市场的增长 [4] - mRNA癌症疫苗和治疗在癌症治疗中发挥关键作用,通过增强免疫系统识别和攻击癌细胞来提高治疗效果和患者预后 [4] 公司概况 - 行业内领先公司专注于开发创新的mRNA癌症疫苗等治疗方案,以提高疗效并满足不断增长的需求 [5][6] - 主要公司包括辉瑞、默克、拜耳、诺华、赛诺菲、阿斯利康、葛兰素史克、罗氏、礼来、莫德纳、BioNTech、再生元等 [6]
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Benzinga· 2024-10-07 01:13
很抱歉,这篇新闻文章没有提供足够的信息供我进行深入的行业和公司研究分析。这篇文章主要列举了一些表现较差的大盘股,但并没有详细介绍这些公司的具体情况和行业动态。我无法从中提取出有价值的关键要点。如果您有其他更详细的公司或行业相关新闻,我很乐意进行深入分析,为您提供专业的研究意见。
MRNA DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
GlobeNewswire News Room· 2024-10-06 23:13
文章核心观点 - 根据诉讼,在整个Class Period期间,被告做出了虚假和/或误导性陈述,和/或未能披露:(1)mRNA-1345,一种旨在保护60岁及以上成人免受RSV感染引起的下呼吸道疾病的mRNA呼吸道合胞病毒(RSV)疫苗,其疗效低于被告所宣称的水平[3] - 因此,mRNA-1345的临床和/或商业前景被夸大了[3] - 当真实情况进入市场时,投资者遭受损失[3] 根据相关目录分别进行总结 公司概况 - Moderna Inc.(纳斯达克代码:MRNA)是一家生物技术公司,专注于开发mRNA疫苗和治疗[无] 行业概况 - 公司主要从事呼吸道合胞病毒(RSV)疫苗的研发[3] 本次诉讼 - 根据诉讼,Moderna公司在2023年1月18日至2024年6月25日期间(Class Period)做出了虚假和/或误导性陈述[3] - 这些陈述涉及公司的mRNA-1345 RSV疫苗的疗效低于预期[3] - 这导致公司的公开声明在所有相关时期都存在重大虚假和误导[3] - 当真实情况被披露时,投资者遭受损失[3]